Drugs / VG901
VG901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06291935 | Sep 2023 → Apr 2026 overdue | retinitis pigmentosa | VeonGen Therapeutics GmbH | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-01-08 | VeonGen Therapeutics GmbH | Regulatory ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial veongen.com ↗ |
| 2023-08-22 | VeonGen Therapeutics GmbH | Regulatory ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa veongen.com ↗ |
| 2022-10-11 | VeonGen Therapeutics GmbH | Results ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT veongen.com ↗
ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 in ABCA4‐associated Stargardt disease (STGD1). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-08 | VeonGen Therapeutics GmbH | ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial veongen.com ↗ |
| 2024-04-10 | VeonGen Therapeutics GmbH | ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 For the Intravitreal Treatment of Retinitis Pigmentosa veongen.com ↗ |
| 2023-08-22 | VeonGen Therapeutics GmbH | ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa veongen.com ↗ |
| 2022-10-11 | VeonGen Therapeutics GmbH | ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT veongen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VG901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06291935 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a gene therapy, VG901” NCT06291935 ↗ |
| Route | Intravitreal | “single intravitreal dose of VG901” NCT06291935 ↗ |
| Target | CNGA1 | “Recombinant Adeno-associated Virus Vector Expressing CNGA1” NCT06291935 ↗ |